DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the LINCOLN PHARMA LTD (LINCOLN) share price today?

LINCOLN PHARMA LTD (LINCOLN) is trading at ₹597 on the NSE, down 0.79% on the day. Source: DocStoX.

What is the PE ratio of LINCOLN PHARMA LTD?

LINCOLN PHARMA LTD has a price-to-earnings (PE) ratio of 13.6 in the Healthcare sector.

What is the market capitalisation of LINCOLN PHARMA LTD?

LINCOLN PHARMA LTD has a market capitalisation of approximately ₹1,197 crore.

LINCOLN PHARMA LTD

LINCOLN·NSE·Healthcare

₹597.00▼ -4.75 (-0.79%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹590.05

₹600.45

52W₹440

₹77048%

Open

₹599.05

High

₹600.45

Low

₹590.05

Prev Close

₹601.75

Volume

20.4K

VWAP

₹594.92

Snapshot

Key fundamentals

Market Cap

₹1,197 Cr

P/E Ratio

13.61Cheap

P/B Ratio

1.65

EPS

₹43.88

Book Value

₹378.00

ROE

12.30%Average

ROCE

16.00%Decent

Dividend Yield

0.29%

Debt / Equity

0.01Low

Face Value

₹10.00

52W High

₹770.00

52W Low

₹440.00

Sector

Healthcare

Industry

Pharmaceuticals

Expensive

None moatHigh uncertainty

Fair value estimate

₹432

▼ 27.7%downside

Trading at ₹597 — 28% above our estimate

BearFair valueBull

₹367₹432₹611

/100

Business quality — Solid

Growth 32Profitability 49Efficiency 20Valuation 95

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Reasonably priced at 14× earnings

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

12% ROE fading to 12% over ~3 yrs, on ₹378 book

₹382

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹611

Analyst target

No analyst coverage

—

Blended fair value₹432

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Reasonably priced at 14× earnings

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

13.6Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

12.3%Average

Above 15% is considered healthy for Indian equities

ROCE

16.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1,197 Cr

P/B

1.65

EPS

₹43.88

Div Yield

0.29%

What changed

Recent changes

Foreign investors-0.6% stake last quarter
Domestic institutions-0.8% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 13.6×

Growth

Steady

+10% rev CAGR

Profitability

Healthy

12.3% ROE

Financial health

Rock solid

D/E 0.01

Momentum

N/A

No technicals

Today

Trading activity

Delivery %66.5%

Turnover₹121.58L Cr

Trades1,101

VWAP₹594.92

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+9.6%

10Y

+5.3%

Profit

+6.4%

+7.3%

10Y

+13.9%

EPS

+6.4%

+7.1%

10Y

+11.7%

Profile

Pros

Company is almost debt free.

Watch-outs

Cons

The company has delivered a poor sales growth of 9.61% over past five years.
Company has a low return on equity of 13.8% over last 3 years.
Earnings include an other income of Rs.33.4 Cr.
Dividend payout has been low at 4.11% of profits over last 3 years
Working capital days have increased from 159 days to 239 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors sold 0.60 pts; domestic institutions reduced 0.81 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

50%

Promoter

Promoters

49.8%0.00

Public

45.4%+1.42

FII / FPI

4.6%-0.60

DII

0.3%-0.81

Quarterly trend

Ownership over time

Q1 FY27

Promoter49.78%

FII4.60%

DII0.27%

Public45.36%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products [1]